Announcement With the year ending, the UK/EU healthcare regulatory body bundled up new rules and specified the new technologies (AI/ML) adoption to achieve a successful start. The new UK clinical trial rules will be officially unveiled in 2026. Alongside, the EU Biotech Act has exponentially reach...
Announcement enGene Holdings Inc., a known clinical level non-viral genetic medicines company, proudly declared its detalimogene voraplasmid selection by the FDA for its Pilot program to contribute to the manufacturing readiness. The detalimogene voraplasmid is also known as detalimogene and was pr...
Announcement PharmaTher Holdings Ltd., a known speciality life sciences company dedicated to unveiling the therapeutic capabilities of ketamine for neuropsychiatric disorders, has confirmed its closing of the existing declared sale of its Abbreviated New Drug Application (ANDA#217858) for Ketamine...
Announcement tiakis Biotech AG, a leading clinical-level biopharmaceutical company conquering novel therapeutics for cardiovascular and life-threatening pulmonary disease, confirmed the completion of its robust data package to upgrade Tiprelestat into a Phase 2 clinical trial in Pulmonary Arterial...
Announcement TempraMed Technologies Ltd., a leading innovator of advanced temperature-controlled medical devices, is honoured to announce its definitive exclusive distribution partnership with Dolfin Sağlık Ürünleri. The intention of TempraMed to join hands with this Turkish company is ...
Announcement Cleveland Diagnostics, Inc., an advanced commercial-level precision oncology company, proudly shared its FDA approval news for its IsoPSA® in vitro diagnostic (IVD) kit via the Premarket Approval (PMA) process. The IsoPSA is a blood-related test referred to as an aid in the decisio...
Announcement Biolexis Therapeutics, an evolving champion in presenting best-in-class inflammation-targeted and next-generation metabolic therapies, proudly announced its selection for the two presentations at the 2nd Innovation in Obesity Therapeutics Summit. To present the company’s clinica...
Announcement Cardiol Therapeutics Inc., a clinical-level life sciences company known for modernising the anti-fibrotic and anti-inflammatory therapies for heart conditions, has released its strong and impressive data from its ARCHER study. The ARCHER study is a placebo-balanced, randomised, double ...
Announcement After Novo Nordisk reduced the price of its renowned GLP-1 medicines, Eli Lilly is set to put a discount tag on its obesity drug (Zepbound), available via LillyDirect. Here, both pharma companies are trying to reach patients with affordable drugs, but they are stuck in negotiations wi...
Uncountable clinical and financial efforts Where many of the giant pharma, including Novo Nordisk and Takeda, left the cell therapy ground and small biotechs closed their operations, a few players are giving their endless efforts to stretch the modality as long as they can. In the last few months, ...
